|
|
(One intermediate revision not shown.) |
Line 1: |
Line 1: |
| | | |
| ==Crystal Structure of MERS-CoV neutralizing antibody G4 Fab== | | ==Crystal Structure of MERS-CoV neutralizing antibody G4 Fab== |
- | <StructureSection load='5vzr' size='340' side='right' caption='[[5vzr]], [[Resolution|resolution]] 1.57Å' scene=''> | + | <StructureSection load='5vzr' size='340' side='right'caption='[[5vzr]], [[Resolution|resolution]] 1.57Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[5vzr]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5VZR OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5VZR FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5vzr]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5VZR OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5VZR FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.57Å</td></tr> |
- | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=PCA:PYROGLUTAMIC+ACID'>PCA</scene></td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PCA:PYROGLUTAMIC+ACID'>PCA</scene></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5vzr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5vzr OCA], [http://pdbe.org/5vzr PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5vzr RCSB], [http://www.ebi.ac.uk/pdbsum/5vzr PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5vzr ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5vzr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5vzr OCA], [https://pdbe.org/5vzr PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5vzr RCSB], [https://www.ebi.ac.uk/pdbsum/5vzr PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5vzr ProSAT]</span></td></tr> |
| </table> | | </table> |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
Line 17: |
Line 17: |
| </div> | | </div> |
| <div class="pdbe-citations 5vzr" style="background-color:#fffaf0;"></div> | | <div class="pdbe-citations 5vzr" style="background-color:#fffaf0;"></div> |
| + | |
| + | ==See Also== |
| + | *[[Antibody 3D structures|Antibody 3D structures]] |
| + | *[[Sandbox 20009|Sandbox 20009]] |
| + | *[[3D structures of non-human antibody|3D structures of non-human antibody]] |
| == References == | | == References == |
| <references/> | | <references/> |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
- | [[Category: Lk3 transgenic mice]] | + | [[Category: Large Structures]] |
- | [[Category: McLellan, J S]] | + | [[Category: Mus musculus]] |
- | [[Category: Wang, N]] | + | [[Category: McLellan JS]] |
- | [[Category: Wrapp, D]] | + | [[Category: Wang N]] |
- | [[Category: Antibody]] | + | [[Category: Wrapp D]] |
- | [[Category: Immune system]]
| + | |
- | [[Category: Neutralizing]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its emergence in 2012 has caused outbreaks in human populations with case-fatality rates of approximately 36%. As in other coronaviruses, the spike (S) glycoprotein of MERS-CoV mediates receptor recognition and membrane fusion and is the primary target of the humoral immune response during infection. Here we use structure-based design to develop a generalizable strategy for retaining coronavirus S proteins in the antigenically optimal prefusion conformation and demonstrate that our engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV. We also determined high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directed neutralizing antibody. The structures reveal that G4 recognizes a glycosylated loop that is variable among coronaviruses and they define four conformational states of the trimer wherein each receptor-binding domain is either tightly packed at the membrane-distal apex or rotated into a receptor-accessible conformation. Our studies suggest a potential mechanism for fusion initiation through sequential receptor-binding events and provide a foundation for the structure-based design of coronavirus vaccines.
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.,Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS Proc Natl Acad Sci U S A. 2017 Aug 14. pii: 201707304. doi:, 10.1073/pnas.1707304114. PMID:28807998[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017 Aug 14. pii: 201707304. doi:, 10.1073/pnas.1707304114. PMID:28807998 doi:http://dx.doi.org/10.1073/pnas.1707304114
|